DIM-3,5-Cl2

DIM-3,5-Cl2 is a bis-indole-derived compound (CDIM) that acts as a dual inverse agonist of the orphan nuclear receptors NR4A1 (Nur77) and NR4A2 (Nurr1). Developed through a collaboration between the Houston Methodist Research Institute and Texas A&M University, it is primarily being investigated for the treatment of glioblastoma multiforme (GBM). The compound targets the epithelial-to-mesenchymal transition (EMT) process, which is a key driver of treatment resistance and invasiveness in GBM. By downregulating transcription factors and proteins such as TWIST1, Sp1, G9a, β1-integrin, and survivin, DIM-3,5-Cl2 enhances the cytotoxic effects of temozolomide (TMZ) and inhibits tumor cell migration. Preclinical data from intracranial xenograft models have shown that DIM-3,5-Cl2 can extend survival, particularly when used in combination with standard-of-care chemotherapy.

Other names

3,5-dichlorophenyl-diindolylmethane1,1-bis(3'-indolyl)-1-(3,5-dichlorophenyl)methane